+Follow
陈沛嫣
No personal profile
3
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
陈沛嫣
11-04
Share your opinion about this news…
BioNTech Beats Expectations, Gives Update on Cancer Drugs
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3576038173431541","uuid":"3576038173431541","gmtCreate":1612944488126,"gmtModify":1731949606990,"name":"陈沛嫣","pinyin":"cpychenpeiyan","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/f516132514df0424f07a465da205ada0","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":3,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.07","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":367461493068120,"gmtCreate":1730727384489,"gmtModify":1730727437731,"author":{"id":"3576038173431541","authorId":"3576038173431541","name":"陈沛嫣","avatar":"https://static.tigerbbs.com/f516132514df0424f07a465da205ada0","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576038173431541","authorIdStr":"3576038173431541"},"themes":[],"htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/367461493068120","repostId":"1189866244","repostType":2,"repost":{"id":"1189866244","kind":"news","pubTimestamp":1730726556,"share":"https://ttm.financial/m/news/1189866244?lang=&edition=fundamental","pubTime":"2024-11-04 21:22","market":"us","language":"en","title":"BioNTech Beats Expectations, Gives Update on Cancer Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=1189866244","media":"Bloomberg","summary":"BioNTech reported better-than-expected quarterly results helped by solid sales of its variant-adapted Covid-19 vaccines.BioNTech shares gained 3% in premarket trading.Mainz, Germany-based BioNTech’s e","content":"<html><head></head><body><p>BioNTech reported better-than-expected quarterly results helped by solid sales of its variant-adapted Covid-19 vaccines.</p><p>BioNTech shares gained 3% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/89277731b77ac2bcad91d40d2742919b\" tg-width=\"828\" tg-height=\"840\"/></p><p style=\"text-align: start;\">Mainz, Germany-based BioNTech’s earnings per diluted share were €0.81 ($0.88) in the third quarter, according to a statement Monday. Analysts surveyed by Bloomberg expected a loss of €1.84.</p><p style=\"text-align: start;\">Sales came in almost three times higher than anticipated at €1.2 billion, although the company said it still expects to be at the low end of its full-year revenue range of between €2.5 billion to €3.1 billion.</p><p style=\"text-align: start;\">The beat in revenue was largely a result of BioNTech receiving early regulatory approvals in Europe and the UK for its variant-adapted Covid-19 shots, which it makes with Pfizer Inc. That boosted sales compared with the same time last year.</p><p style=\"text-align: start;\">BioNTech gained prominence during the pandemic and still remains dependent on Covid-19 jabs. But it said it’s advancing efforts to become a global multiproduct immunotherapy company, with various cancer drugs and vaccine candidates in its pipeline.</p><p style=\"text-align: start;\">The company has initiated two mid-stage dose optimization studies including for its widely-watched experimental medicine in small-cell lung cancer and triple-negative breast cancer. A mid-stage trial of an mRNA-based individualized cancer vaccine for use in<em> </em>patients with high-risk muscle-invasive urothelial cancer is also on track, it said.</p><p style=\"text-align: start;\">The vaccine maker has suffered a setback for its two-in-one shot against Covid and the flu that it’s developing with Pfizer.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech Beats Expectations, Gives Update on Cancer Drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech Beats Expectations, Gives Update on Cancer Drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-04 21:22 GMT+8 <a href=https://www.bloomberg.com/news/articles/2024-11-04/biontech-beats-expectations-gives-update-on-cancer-drugs><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech reported better-than-expected quarterly results helped by solid sales of its variant-adapted Covid-19 vaccines.BioNTech shares gained 3% in premarket trading.Mainz, Germany-based BioNTech’s ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2024-11-04/biontech-beats-expectations-gives-update-on-cancer-drugs\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.bloomberg.com/news/articles/2024-11-04/biontech-beats-expectations-gives-update-on-cancer-drugs","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189866244","content_text":"BioNTech reported better-than-expected quarterly results helped by solid sales of its variant-adapted Covid-19 vaccines.BioNTech shares gained 3% in premarket trading.Mainz, Germany-based BioNTech’s earnings per diluted share were €0.81 ($0.88) in the third quarter, according to a statement Monday. Analysts surveyed by Bloomberg expected a loss of €1.84.Sales came in almost three times higher than anticipated at €1.2 billion, although the company said it still expects to be at the low end of its full-year revenue range of between €2.5 billion to €3.1 billion.The beat in revenue was largely a result of BioNTech receiving early regulatory approvals in Europe and the UK for its variant-adapted Covid-19 shots, which it makes with Pfizer Inc. That boosted sales compared with the same time last year.BioNTech gained prominence during the pandemic and still remains dependent on Covid-19 jabs. But it said it’s advancing efforts to become a global multiproduct immunotherapy company, with various cancer drugs and vaccine candidates in its pipeline.The company has initiated two mid-stage dose optimization studies including for its widely-watched experimental medicine in small-cell lung cancer and triple-negative breast cancer. A mid-stage trial of an mRNA-based individualized cancer vaccine for use in patients with high-risk muscle-invasive urothelial cancer is also on track, it said.The vaccine maker has suffered a setback for its two-in-one shot against Covid and the flu that it’s developing with Pfizer.","news_type":1},"isVote":1,"tweetType":1,"viewCount":130,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":367461493068120,"gmtCreate":1730727384489,"gmtModify":1730727437731,"author":{"id":"3576038173431541","authorId":"3576038173431541","name":"陈沛嫣","avatar":"https://static.tigerbbs.com/f516132514df0424f07a465da205ada0","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576038173431541","authorIdStr":"3576038173431541"},"themes":[],"htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/367461493068120","repostId":"1189866244","repostType":2,"repost":{"id":"1189866244","kind":"news","pubTimestamp":1730726556,"share":"https://ttm.financial/m/news/1189866244?lang=&edition=fundamental","pubTime":"2024-11-04 21:22","market":"us","language":"en","title":"BioNTech Beats Expectations, Gives Update on Cancer Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=1189866244","media":"Bloomberg","summary":"BioNTech reported better-than-expected quarterly results helped by solid sales of its variant-adapted Covid-19 vaccines.BioNTech shares gained 3% in premarket trading.Mainz, Germany-based BioNTech’s e","content":"<html><head></head><body><p>BioNTech reported better-than-expected quarterly results helped by solid sales of its variant-adapted Covid-19 vaccines.</p><p>BioNTech shares gained 3% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/89277731b77ac2bcad91d40d2742919b\" tg-width=\"828\" tg-height=\"840\"/></p><p style=\"text-align: start;\">Mainz, Germany-based BioNTech’s earnings per diluted share were €0.81 ($0.88) in the third quarter, according to a statement Monday. Analysts surveyed by Bloomberg expected a loss of €1.84.</p><p style=\"text-align: start;\">Sales came in almost three times higher than anticipated at €1.2 billion, although the company said it still expects to be at the low end of its full-year revenue range of between €2.5 billion to €3.1 billion.</p><p style=\"text-align: start;\">The beat in revenue was largely a result of BioNTech receiving early regulatory approvals in Europe and the UK for its variant-adapted Covid-19 shots, which it makes with Pfizer Inc. That boosted sales compared with the same time last year.</p><p style=\"text-align: start;\">BioNTech gained prominence during the pandemic and still remains dependent on Covid-19 jabs. But it said it’s advancing efforts to become a global multiproduct immunotherapy company, with various cancer drugs and vaccine candidates in its pipeline.</p><p style=\"text-align: start;\">The company has initiated two mid-stage dose optimization studies including for its widely-watched experimental medicine in small-cell lung cancer and triple-negative breast cancer. A mid-stage trial of an mRNA-based individualized cancer vaccine for use in<em> </em>patients with high-risk muscle-invasive urothelial cancer is also on track, it said.</p><p style=\"text-align: start;\">The vaccine maker has suffered a setback for its two-in-one shot against Covid and the flu that it’s developing with Pfizer.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech Beats Expectations, Gives Update on Cancer Drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech Beats Expectations, Gives Update on Cancer Drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-04 21:22 GMT+8 <a href=https://www.bloomberg.com/news/articles/2024-11-04/biontech-beats-expectations-gives-update-on-cancer-drugs><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech reported better-than-expected quarterly results helped by solid sales of its variant-adapted Covid-19 vaccines.BioNTech shares gained 3% in premarket trading.Mainz, Germany-based BioNTech’s ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2024-11-04/biontech-beats-expectations-gives-update-on-cancer-drugs\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.bloomberg.com/news/articles/2024-11-04/biontech-beats-expectations-gives-update-on-cancer-drugs","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189866244","content_text":"BioNTech reported better-than-expected quarterly results helped by solid sales of its variant-adapted Covid-19 vaccines.BioNTech shares gained 3% in premarket trading.Mainz, Germany-based BioNTech’s earnings per diluted share were €0.81 ($0.88) in the third quarter, according to a statement Monday. Analysts surveyed by Bloomberg expected a loss of €1.84.Sales came in almost three times higher than anticipated at €1.2 billion, although the company said it still expects to be at the low end of its full-year revenue range of between €2.5 billion to €3.1 billion.The beat in revenue was largely a result of BioNTech receiving early regulatory approvals in Europe and the UK for its variant-adapted Covid-19 shots, which it makes with Pfizer Inc. That boosted sales compared with the same time last year.BioNTech gained prominence during the pandemic and still remains dependent on Covid-19 jabs. But it said it’s advancing efforts to become a global multiproduct immunotherapy company, with various cancer drugs and vaccine candidates in its pipeline.The company has initiated two mid-stage dose optimization studies including for its widely-watched experimental medicine in small-cell lung cancer and triple-negative breast cancer. A mid-stage trial of an mRNA-based individualized cancer vaccine for use in patients with high-risk muscle-invasive urothelial cancer is also on track, it said.The vaccine maker has suffered a setback for its two-in-one shot against Covid and the flu that it’s developing with Pfizer.","news_type":1},"isVote":1,"tweetType":1,"viewCount":130,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
